Argenica Therapeutics ASXAGN Webinar with Dr Liz Dallimore 160824

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=_GDOPPWIOqE

Watch our webinar with Argenica Therapeutics, featuring Managing Director Dr. Liz Dallimore. • The webinar includes an interview and a live Q A with the audience. • Key topics: • Overview of Argenica Therapeutics • Opportunity in stroke • Phase 2 clinical trial • Competitive advantages in the Biotech industry • Key challenges • Team at Argenica • Catalysts and milestones for the next 12-18 months • Long-term outlook for the company • Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries. In June 2021, the Company listed on the ASX, and has since completed a successful Phase 1 clinical trial proving the safety and tolerability of its drug in healthy human volunteers, and is currently dosing acute ischaemic stroke patients in a Phase 2 clinical trial in Australia. The Company has a favourable competitive landscape and commercial opportunity, with no other universal marketed drugs available to protect brain cells from death following stroke. • // • The information provided in our webinars are for general advice purposes only and should not be construed as a recommendation or endorsement of any financial product or security. • Sharewise is a stock trading platform seamlessly integrated with expert advice. We will be launching later this year. Keep an eye out for updates. • Website: www.sharewise.com.au • Facebook: / sharewiseau • LinkedIn: / sharewiseau • Instagram: / sharewise • TikTok: / sharewiseau

#############################

New on site